Investing, Stocks, Stocks to Buy, Videos

Pfizer Stock Looks Undervalued: Is a 30% Rally Coming?

Written by: Rick Orford

Edited by: Rick Orford

Last Updated February 20, 2026

Disclaimer

This content is not intended to provide financial advice; rather, it’s for information and entertainment purposes only.

Always consult a licensed advisor for investment decisions.

Some of the links in this article may be affiliate links. If you click on a link, the affiliate may provide compensation to this site at no cost to you, regardless if you decide to purchase something. You can read our affiliate disclosure in our privacy policy.

Finally, this article has been written, reviewed, and fact-checked. Portions of this article have been written using assistive AI tools to help with tasks like research, spell-checking, grammar, and translation. Please have a look at our editorial guidelines for more information about how we create content.

Pfizer (NYSE: PFE) is trading at just 9 times earnings with a 6% yield, and analysts see up to 30% upside. Is the market underestimating its cash flow, dividend strength, and global scale? I break down the numbers and reveal why this defensive giant could quietly surprise investors in 2026.

Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 19, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.

Share this post:

X (Twitter) Facebook Pinterest LinkedIn Email

Previous

Amcor Stock Could Quietly Soar With a 5.3% Dividend

Next

Exxon Mobil Stock: The Cash Cow Investors Are Flocking To Before the Next Crash